Tag: half

In the first half of 2025, revenue amounted to €7,115 thousand (H1 2024: €7,809 thousand). The decline was mainly due to a more competitive pricing strategy that was implemented on the Textmagic platform. EBITDA was €2,581 thousand (H1 2024: €3,149 thousand), and the operating loss totaled to €123 thousand (H1 2024: operating profit of €1,097 thousand). Profitability was negatively affected by an increase in amortization expenses of €652 thousand, resulting from the higher volume of development activities in previous periods with the goal of improving the value proposition.

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.021 per Unit, for total gross proceeds to Revive of $60,900. Furthermore, the Company announces that it has settled an amount of $67,400 owing pursuant to an arm’s length note through the issuance of 3,209,523 Units, at a price of $0.021 per Unit, being the same issue price and security offered pursuant to the Offering.